In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
Bharat Biotech invests $75 million in India's first Cell & Gene Therapy facility, focusing on advanced therapies and ...
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare ...
Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...
Our Bureau, Bengaluru Thursday, March 20, 2025, 17:40 Hrs [IST] ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne ...
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results